March 18th 2024
AstraZeneca is the second pharmaceutical company to cap out-of-pocket costs for eligible patients.
March 8th 2024
Risks and Liabilities in Pharmacy Practice
1.0 Credit / Law
View More
Exploring the New Standard of Care for the Frontline Treatment of Non-Small Cell Lung Cancer: A Focus on Immunotherapy
1.5 Credits / Oncology, Pulmonology/Respiratory
View More
An Article in the American Journal of Managed Care’s Evidence-Based Oncology: Navigating the Complexities of Frontline Immunotherapy in NSCLC
2 Credits / Oncology, Pulmonology/Respiratory
View More
Uncovering the Economic Burden of Chronic Cough and the Promising Role of Emerging Targeted Therapies
3.0 Credits / Pulmonology/Respiratory
View More
Targeted Therapies for Non-Small Cell Lung Cancer With ROS1 or KRAS Mutations and the Impact of Pharmacists’ Care
1.0 Credit / Oncology, Pulmonology/Respiratory
View More
Perspectives on Emerging Data for the Use of Immunotherapy in the Treatment of Early-Stage Non-Small Cell Lung Cancer
1.5 Credits / Oncology, Pulmonology/Respiratory
View More
Evolving Treatment Strategies in the Management of Pulmonary Arterial Hypertension: Key Insights for the Pharmacist, featuring a Patient Perspective
1.5 Credits / Pulmonology/Respiratory
View More
Advances in EGFR Exon 20 Insertion-Positive Non–Small Cell Lung Cancer: A Focus on Specialty Pharmacy Interventions
1.5 Credits / Oncology, Pulmonology/Respiratory
View More
Reducing the Incidence and Severity of RSV in Older Adults: Opportunities for Patient Identification and Vaccination Counseling
1.0 Credit / Infectious Diseases, Pulmonology/Respiratory
View More
Exploring Recent Advances in the Treatment of COPD: An Update for Pharmacists
0.75 Credit / Pulmonology/Respiratory
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Novel Therapeutic Approaches for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer: An Oncology Pharmacy Perspective
1.0 Credit / Oncology, Pulmonology/Respiratory
View More
Practical Approaches in the Management of Pulmonary Arterial Hypertension: Understanding the Pharmacist’s Role in Personalized Care
1.0 Credit / Pulmonology/Respiratory
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Advances and Best Practices for Managed Care Pharmacists and the Treatment of Patients with Alpha-1 Antitrypsin Deficiency
1.0 Credit / Pulmonology/Respiratory
View More
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Diseases, Respiratory, Immunization
View More
Integrating Guideline-Driven Protocols Into Evidence-Based Practice to Improve Outcomes in Patients With Pulmonary Arterial Hypertension
1.0 Credit / Respiratory
View More
GASp, Where’s the Amoxicillin? Group A Streptococcus Infections and What Pharmacists Need to Know
1.0 Credit / Pulmonology/Respiratory
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Exploring the GOLD Report Updates and the Value of Patient-Centered Strategies for the Treatment of Chronic Obstructive Pulmonary Disease: Opportunities to Reduce Health Burde...
1.0 Credit / Pulmonology/Respiratory
View More
Exploring the GOLD Report Updates and the Value of Patient-Centered Strategies for the Treatment of Chronic Obstructive Pulmonary Disease: Opportunities to Reduce Health Burde...
1.0 Credit / Pulmonology/Respiratory
View More
Moderna’s mRNA RSV Vaccine Shows Positive Results in Phase 3 Trial
January 3rd 2024The vaccine, called mRNA-1345, demonstrated an efficacy of 83.7% against RSV-associated lower respiratory tract disease with at least 2 signs or symptoms and 82.4% against the disease with at least 3 signs or symptoms.
Sanofi, AstraZeneca Will Release Additional Doses of Nirsevimab-Alip to Meet Unprecendented Demand
December 19th 2023In January 2024, Sanofi and AstraZenenca will release 230,000 additional doses of nirsevimab-alip, heeding guidance from the CDC to leverage all tools to increase immunizations against RSV.
COPD Exacerbations Reduced Substantially With Dupilumab, Phase 3 Data Shows
November 27th 2023The NOTUS trial was shown to have successfully achieved its primary endpoint, demonstrating the notable efficacy of dupilumab in reducing exacerbations by 34% versus placebo in individuals with moderate-to-severe COPD showing evidence of type 2 inflammation.